Next Article in Journal
UBC® Rapid Test—A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study
Next Article in Special Issue
GPR68: An Emerging Drug Target in Cancer
Previous Article in Journal
Human Miro Proteins Act as NTP Hydrolases through a Novel, Non-Canonical Catalytic Mechanism
Previous Article in Special Issue
Transcriptional Landscape of PARs in Epithelial Malignancies
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(12), 3840; https://doi.org/10.3390/ijms19123840

GPCR Modulation in Breast Cancer

1
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
2
Laboratoire des Biomolécules, CNRS-UM7203, Sorbonne University, Ecole Normale Supérieure, F-75252 Paris, France
*
Authors to whom correspondence should be addressed.
Received: 3 November 2018 / Revised: 22 November 2018 / Accepted: 27 November 2018 / Published: 2 December 2018
(This article belongs to the Special Issue Cancer-Driver G Protein-Coupled Receptors as Therapeutic Targets)
  |  
PDF [5606 KB, uploaded 13 December 2018]
  |  

Abstract

Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration. G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors involved in the development and progression of many tumors including breast cancer. Here we discuss data regarding GPCR-mediated signaling, pharmacological properties and biological outputs toward breast cancer tumorigenesis and metastasis. Furthermore, we address several drugs that have shown an unexpected opportunity to interfere with GPCR-based breast tumorigenic signals. View Full-Text
Keywords: GPCRs; breast cancer; signal transduction GPCRs; breast cancer; signal transduction
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lappano, R.; Jacquot, Y.; Maggiolini, M. GPCR Modulation in Breast Cancer. Int. J. Mol. Sci. 2018, 19, 3840.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top